Angiotensin receptor blocker after valve replacement for severe aortic stenosis with thickened heart muscle
Tests an angiotensin receptor blocker in people after valve replacement for severe aortic stenosis.
Key facts
- Who runs it
- Seoul National University Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 632 people, planned
- Started
- 15 Aug 2026
- Expected to end
- 15 Jun 2030
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Angiotensin Receptor Blocker (ARB)
- Record updated
- 29 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe, symptom-causing aortic stenosis and a thickened heart muscle who had a successful TAVR in the last 30 days. People get an ARB medicine or no ARB.
- Age
- 40 years or older
- Sex
- Male or female
- Disease stage
- Symptomatic severe aortic stenosis (valve area ≤1.0 cm², valve area index ≤0.6 cm²/m², mean gradient ≥40 mmHg, or peak velocity ≥4.0 m/sec). Left ventricular hypertrophy (mass index >115 g/m² in men, >95 g/m² in women). Heart pumping strength (LVEF) >40% before TAVR.
- Earlier treatment
- Must have had a successful TAVR (native-valve or valve-in-valve) within the prior 30 days, meeting all VARC-3 success criteria.
Main reasons for not taking part
- Low blood pressure (systolic <90 mmHg) or need for continuous IV drugs to support blood pressure
- High blood potassium (>5.5 mmol/L)
- Allergy or past intolerance to angiotensin receptor blockers
- Pregnancy, breastfeeding, or planning a pregnancy
- eGFR <30 mL/min/1.73 m^2 or on kidney replacement therapy; acute coronary syndrome in the past 1 year; life expectancy under 2 years
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male or female aged 40 years or older
- Symptomatic severe aortic stenosis (AS) with left ventricular hypertrophy (LVH) who successfully underwent transcatheter aortic valve replacement (TAVR) within the prior 30 days, including native-valve or valve-in-valve TAVR; Severe AS defined by at least one of the following: aortic valve area ≤1.0 cm²; aortic valve area index ≤0.6 cm²/m²; mean pressure gradient ≥40 mmHg; or maximal aortic valve velocity ≥4.0 m/sec; LVH defined as left ventricular mass index >115 g/m² in men or >95 g/m² in women
- Successful TAVR (technical success) meeting all VARC-3 criteria: survival; successful access, delivery, and retrieval of the device; correct positioning of a single prosthetic valve in the proper anatomic location; no additional surgery or procedure related to the device (excluding permanent pacemaker implantation) or to major vascular, access-site, or cardiac structural complications; and intended prosthetic valve performance (mean gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation)
- Left ventricular ejection fraction (LVEF) >40% before TAVR
- Provided written informed consent to participate, either voluntarily or through a legal representative
Who cannot take part
- Allergy, hypersensitivity, or prior intolerance to angiotensin receptor blockers
- Acute coronary syndrome diagnosed within the past 1 year
- Any other medical condition that, in the investigator's judgment, makes participation in the trial inappropriate
- Hyperkalemia (serum potassium >5.5 mmol/L)
- Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m\^2 by the CKD-EPI equation, or currently undergoing renal replacement therapy
- Hypotension (systolic blood pressure <90 mmHg) or hemodynamic instability defined as a need for continuous intravenous vasopressor support at screening
- Bilateral renal artery stenosis without stent placement
- Pregnancy, breastfeeding, or planning to become pregnant
- Estimated life expectancy of less than 2 years
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, prospective, open-label, randomized, investigator-initiated trial evaluating whether angiotensin receptor blocker (ARB) therapy improves clinical outcomes in patients with severe aortic stenosis (AS) and left ventricular hypertrophy (LVH) who have undergone transcatheter aortic valve replacement (TAVR).
Read full original descriptionShow less
Severe AS imposes chronic pressure overload on the left ventricle, leading to LVH as a compensatory response. While initially adaptive, sustained LVH promotes myocardial fibrosis, reduced ventricular compliance, and impaired cardiac function. LVH that persists after valve replacement is associated with increased morbidity and mortality, including a higher risk of heart failure. Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACEi) or ARBs has been proposed as a strategy to attenuate adverse left ventricular remodeling after valve replacement by inhibiting angiotensin II-mediated hypertrophic and fibrotic signaling. However, evidence in TAVR patients with LVH remains limited, and a small randomized trial of an ACEi reported drug discontinuation in approximately 10% of patients due to dry cough. The ARBITAR trial therefore evaluates the clinical efficacy of an ARB in this population.
A total of 632 patients with symptomatic severe AS and LVH who have successfully undergone TAVR within the prior 30 days will be randomized 1:1 to receive an ARB (experimental group) or no ARB (control group), stratified by site and sex. Assigned treatment is continued for up to 24 months, with follow-up visits at 1, 6, 12, and 24 months. In the experimental group, the ARB (candesartan, losartan, or valsartan) is up-titrated toward a target dose. ACE inhibitors, direct renin inhibitors, and angiotensin receptor/neprilysin inhibitors are prohibited in both groups.
The primary endpoint is the composite of all-cause death or admission for heart failure over 2 years. Secondary endpoints include the individual components of the primary endpoint and other clinical events, as well as echocardiographic measures, NT-proBNP, NYHA functional class, and KCCQ-12 score. The primary analysis follows the intention-to-treat principle.
The 2 groups in the trial
- Angiotensin Receptor Blocker (ARB) GroupTreatment being tested
Participants in this group receive an angiotensin receptor blocker (candesartan, losartan, or valsartan) in addition to standard care after TAVR. As a principle, the ARB is up-titrated toward the target daily dose, but it may be initiated at a lower starting dose based on clinical need. Assigned treatment is continued for up to 24 months. ACE inhibitors, direct renin inhibitors, and angiotensin receptor/neprilysin inhibitors are prohibited.
Treatment: Angiotensin Receptor Blocker (ARB)
- Control (No ARB) GroupNo study treatment, for comparison
Participants in this group receive standard care after TAVR without any angiotensin receptor blocker during the study period. ACE inhibitors, direct renin inhibitors, and angiotensin receptor/neprilysin inhibitors are also prohibited in this group. Participants are followed for up to 24 months.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Angiotensin Receptor Blockade In Patients After Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR) Trial
- Plain-language title
- Angiotensin receptor blocker after valve replacement for severe aortic stenosis with thickened heart muscleGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 July 2026